AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24308190
Drug: Acupuncture intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acupuncture intervention combined with hyperbaric oxygen therapy
Trial: 24308190
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (hyperbaric oxygen therapy only)
Trial: 16797249
Drug: Onercept 10
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 10 mg
Trial: 16797249
Drug: Onercept 25
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 25 mg
Trial: 16797249
Drug: Onercept 35
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 35 mg
Trial: 16797249
Drug: Onercept 50
RxNorm normalized name: Onercept
DrugBank: Onercept (DB06495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onercept 50 mg
Trial: 12878450
Drug: Head cooling
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head cooling combined with minimal hypothermia (rectal temperature 36.5-36 degrees C) for 72 hours
Trial: 12878450
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (Group 1a)
Trial: 8416666
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g fish oil/d (50% n‐3 fatty acids)
Trial: 8416666
Drug: 12 g
RxNorm normalized name: PEG-12 GLYCERYL LAURATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 g fish oil/d (50% n‐3 fatty acids)
Trial: 3484505
Drug: Vaccine intervention
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine intervention (specifics not provided)
Trial: 17341882
Drug: Mistletoe infusion
RxNorm normalized name: MISTLETOE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mistletoe infusion (Iscador)
Trial: 3220614
Drug: Diphenhydramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (50 mg or 75 mg)
Trial: 31820121
Drug: Risedronate (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (35 mg) with cholecalciferol (5600 IU)
Trial: 31820121
Drug: Risedronate (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (35 mg) alone
Trial: 17550040
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied vitamin 'E' (100 mg twice daily)
Trial: 17550040
Drug: Systemically administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemically administered vitamin 'E'
Trial: 15970639
Drug: Nasal rinsing
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal rinsing with hypertonic saline (3 times daily for 7 weeks)
Trial: 10073976
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive use with factor II:A20210
Trial: 10073976
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive use with factor V:A1691
Trial: 1959365
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (7 mg in 14 mL of sterile saline)
Trial: 1959365
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline 14 mL)
Trial: 28378356
Drug: Processed Nigella
RxNorm normalized name: Nigella sativa seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Processed Nigella sativa seed powder (2 g/day in divided doses)
Trial: 20595643
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (2 capsules and 4 cups water/d)
Trial: 20605696
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (4 cups water/d)
Trial: 17692724
Drug: Garenoxacin (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garenoxacin (oral or intravenous) 50-1200 mg/d for 1 to 28 days
Trial: 15453552
Drug: Control oral
RxNorm normalized name: Dayquil Mucus Control Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control oral appliance
Trial: 9802141
Drug: Ramipril 10
RxNorm normalized name: ramipril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 10 mg o.d.
Trial: 7543352
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of rhGM‐CSF, 250 micrograms/m2/day (trial 1)
Trial: 7543352
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of rhGM‐CSF, 250 micrograms/m2/day (trial 2)
Trial: 2083956
Drug: Nebuhaler (conical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebuhaler (conical spacer with inhalation valve)
Trial: 28429365
Drug: Screwed implant-abutment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Screwed implant-abutment connection (Group 1)
Trial: 28429365
Drug: Cemented implant-abutment
RxNorm normalized name: Cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemented implant-abutment connection (Group 2)
Trial: 26027630
Drug: Alirocumab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (75 mg every 2 weeks, increased to 150 mg Q2W at week 12 if LDL-C ≥70 mg/dL)
Trial: 23529851
Drug: Group HDO
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group HDO (haloperidol 2 mg, dexamethasone 8 mg, ondansetron)
Trial: 24565295
Drug: Group O
RxNorm normalized name: plasma, human, blood group O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group O (ondansetron 8 mg)
Trial: 18795629
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg, once daily) after ESWL
Trial: 8630960
Drug: Chamomile mouthwash,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamomile mouthwash, administered thrice daily for 14 days.
Trial: 8630960
Drug: Placebo mouthwash,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mouthwash, administered thrice daily for 14 days.
Trial: 10149894
Drug: Hercules injections
RxNorm normalized name: Hercules Club Whole
DrugBank: Zanthoxylum clava-herculis whole (DB14353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hercules injections
Trial: 10149894
Drug: Conventional manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional manual injections
Trial: 31436395
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care (SoC; intensive chemotherapy)
Trial: 27553751
Drug: Subcutaneous mepolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous mepolizumab treatment
Trial: 20929607
Drug: Plasma kallikrein
RxNorm normalized name: Plasma kallikrein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma kallikrein inhibitor
Trial: 20929607
Drug: Bradykinin B₂‐receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bradykinin B₂‐receptor antagonist
Trial: 12679754
Drug: Clopidogrel +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel + Aspirin
Trial: 18232183
Drug: Miglitol 50
RxNorm normalized name: miglitol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol 50 mg three times daily for 12 weeks
Trial: 3700932
Drug: Doxepin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin (10 to 20 mg daily)
Trial: 25164259
Drug: Group-based dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based dietary intervention (individualized calorie goals, weight maintenance advice, Dietary Approaches to Stop Hypertension dietary pattern, weekly group meetings)
Trial: 23866514
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba (120 mg daily dose)
Trial: 23866514
Drug: Rivastigmine (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivastigmine (4.5 mg daily dose)
Trial: 18785988
Drug: LAB4 multistrain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAB4 multistrain probiotic preparation (2.5 × 10(10) cfu/capsule)
Trial: 17468062
Drug: Intravenous zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous zoledronic acid (ZOL) 5 mg
Trial: 17468062
Drug: Oral alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alendronate (ALN) 70 mg
Trial: 8116042
Drug: Adjunct treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct treatment with 10 courses of photochemotherapy (PCT)
Trial: 8116042
Drug: Adjunct treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunct treatment with 20 courses of photochemotherapy (PCT)
Trial: 8116042
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no additional treatment
Trial: 3136642
Drug: High lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High lysine (206 mg.kg‐1.d‐1)
Trial: 3136642
Drug: Low lysine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low lysine (158 mg.kg‐1.d‐1)
Trial: 3136642
Drug: High threonine
RxNorm normalized name: Threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High threonine (147 mg.kg‐1.d‐1)
Trial: 3136642
Drug: Low threonine
RxNorm normalized name: Threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low threonine (113 mg.kg‐1.d‐1)
Trial: 3136642
Drug: High histidine
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High histidine (124 mg.kg‐1.d‐1)
Trial: 3136642
Drug: Low histidine
RxNorm normalized name: Histidine
DrugBank: Histidine (DB00117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low histidine (85 mg.kg‐1.d‐1)
Trial: 31361922
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZOL) 5 mg annually
Trial: 21788827
Drug: Postmastectomy radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postmastectomy radiation therapy on tissue expanders (group 2)
Trial: 21788827
Drug: Postmastectomy radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postmastectomy radiation therapy on permanent implants (group 1)
Trial: 14627176
Drug: losartan/HCTZ (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan/HCTZ (50 mg/12.5 mg)
Trial: 11128853
Drug: Running for
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Running for 35 min with FDG injection after 15 min; FDG uptake in lower leg muscles increased from 24.6 +/- 9.5% to 43.1 +/- 4.7%; P < 0.05
Trial: 11128853
Drug: Running for
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Running for 35 min with FDG injection after 15 min; FDG uptake in heart increased from 2.3 +/- 0.4% to 2.8 +/- 0.6%; P < 0.05
Trial: 11128853
Drug: Resting for
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Resting for 35 min after FDG injection; FDG uptake in abdominal region reduced from 37.3 +/- 7.2% to 19.7 +/- 4.9%; P < 0.05
Trial: 11128853
Drug: Running for
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Running for 35 min with FDG injection after 15 min; FDG uptake in brain remained stable at 11.9 +/- 2.8% at rest and 10.3 +/- 2.5% after exercise; P not specified
Trial: 9175961
Drug: Combined spinal-extradural
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined spinal-extradural technique with 2.25 ml of 0.5% hyperbaric bupivacaine
Trial: 3083995
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg prednisolone daily
Trial: 3083995
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg prednisolone daily
Trial: 3083995
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg prednisolone daily
Trial: 26924243
Drug: Camicinal 125
RxNorm normalized name: Camicinal
DrugBank: Camicinal (DB12567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camicinal 125 mg
Trial: 26924243
Drug: Camicinal 25
RxNorm normalized name: Camicinal
DrugBank: Camicinal (DB12567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camicinal 25 mg
Trial: 28782145
Drug: Camicinal 50
RxNorm normalized name: Camicinal
DrugBank: Camicinal (DB12567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camicinal 50 mg
Trial: 23801256
Drug: Aripiprazole (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (mean dose 5.5 mg/day)
Trial: 23801256
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean dose 1.12 mg/day)
Trial: 20082200
Drug: Intraoperative orbital
RxNorm normalized name: barbital
DrugBank: Barbital (DB01483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative orbital floor triamcinolone acetonide (1 ml = 40 mg)
Trial: 20082200
Drug: 4‐week postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4‐week postoperative oral prednisolone
Trial: 19013239
Drug: 0.3% DHEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% DHEA cream
Trial: 19013239
Drug: 1% DHEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% DHEA cream
Trial: 19013239
Drug: 2% DHEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% DHEA cream
Trial: 19013239
Drug: Topical DHEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical DHEA
Trial: 19013239
Drug: Placebo (0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0% DHEA cream)
Trial: 15907404
Drug: Lacidipine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine (4 mg/day, n = 48)
Trial: 10721943
Drug: Primary adjuvant
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary adjuvant therapy
Trial: 14724725
Drug: Continuous lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous lateral rotational therapy (CLRT)
Trial: 2019190
Drug: Conventional bed
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional bed treatment (turned every 2 hours)
Trial: 2019190
Drug: Conventional bed
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional bed treatment
Trial: 6290435
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg oral
Trial: 28874171
Drug: Galium‐Heel® (low‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galium‐Heel® (low‐dose multicomponent medicine) administered twice a day for six non‐consecutive months
Trial: 28874171
Drug: Galium‐Heel® (low‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galium‐Heel® (low‐dose multicomponent medicine)
Trial: 19268614
Drug: Tailored behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored behavioural treatment protocol (TBT)
Trial: 19268614
Drug: Exercise based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise based physical therapy protocol (EBT)
Trial: 14707796
Drug: Birth weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birth weight <3000 g
Trial: 9885731
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with grass pollen extract (9,500 BU/ml)
Trial: 8004299
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (5 mg x 2)
Trial: 8004299
Drug: Intravenous albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous albuterol (0.5 mg)
Trial: 2591460
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g Heptaminol Adenosine Phosphate (HAP)
Trial: 1242861
Drug: Beclomethasone Dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone Dipropionate (12 metered-doses per day)
Trial: 1242861
Drug: Dexamethasone Isonicotinate
RxNorm normalized name: Dexamethasone isonicotinate
DrugBank: Dexamethasone isonicotinate (DB11487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone Isonicotinate (12 metered-doses per day)
Trial: 31821452
Drug: Amoxicillin (7-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (7-day therapy)
Trial: 31775353
Drug: Supplement A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement A (50 mg of blackcurrant anthocyanin)
Trial: 31775353
Drug: Supplement B
RxNorm normalized name: Lipotropic Adju Lipot Supplement B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement B (50 mg of blackcurrant anthocyanin plus vitamin E)
Trial: 27128218
Drug: AZD7325 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7325 2 mg
Trial: 27128218
Drug: AZD7325 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7325 10 mg
Trial: 17989272
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi Chuan twice a week for 16 weeks
Trial: 14508838
Drug: Standard fractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fractionated radiation treatment arm
Trial: 14508838
Drug: Hyperfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiation treatment arm
Trial: 11199361
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg once daily (QD)
Trial: 11199361
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg twice daily (BID)
Trial: 11199361
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily (QD)
Trial: 1589586
Drug: Lithium (steady-state
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (steady-state serum levels 0.9-1.3 mEq/L)
Trial: 27760998
Drug: febuxostat 40 mg
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: febuxostat 40 mg
Trial: 27760998
Drug: benzbromarone 50 mg
RxNorm normalized name: benzbromarone
DrugBank: Benzbromarone (DB12319)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benzbromarone 50 mg
Trial: 27760998
Drug: febuxostat 20 mg
RxNorm normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: febuxostat 20 mg and benzbromarone 25 mg (feb/ben)
Trial: 25645166
Drug: Control activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control activity (e.g., reading newspaper)
Trial: 18181335
Drug: Oral nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral nifedipine (10 mg every 20 minutes, max 40 mg in the first hour, then 20 mg every 4 hours for up to 72 hours)
Trial: 18181335
Drug: Intravenous terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous terbutaline (initially infused at 10 microg/min, increased to max 25 microg/min, then switched to subcutaneous injection of 0.25 mg every 4 hours for 24 hours)
Trial: 15152270
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg orally
Trial: 11282906
Drug: NO synthase
RxNorm normalized name: nitric oxide synthase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO synthase inhibitor Nomega-nitro-L-arginine (L-NNA) in NC
Trial: 8096703
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) alone at a maintenance dose of 250 mg every 6 h
Trial: 8096703
Drug: Cotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotherapy with acyclovir (ACV) at 800 mg every 6 h
Trial: 31859541
Drug: Benralizumab 30
RxNorm normalized name: benralizumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab 30 mg (every 4 weeks or 8 weeks; first three doses every 4 weeks)
Trial: 31300494
Drug: Oxygen 70
RxNorm normalized name: oxygen 70 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen 70 L/min, airway opened by laryngoscopy
Trial: 31300494
Drug: Oxygen 70
RxNorm normalized name: oxygen 70 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen 70 L/min with jaw thrust
Trial: 31300494
Drug: Oxygen 10
RxNorm normalized name: oxygen 10 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen 10 L/min with jaw thrust
Trial: 31300494
Drug: Oxygen 2
RxNorm normalized name: oxygen 2 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen 2 L/min with jaw thrust